Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) Equity Income (2022 - 2023)

Silo Pharma (SILO) has disclosed Equity Income for 2 consecutive years, with -$3508.0 as the latest value for Q2 2023.

  • Quarterly Equity Income rose 94.11% to -$3508.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was -$78329.0 through Dec 2023, changed N/A year-over-year, with the annual reading at -$3118.0 for FY2023, 99.06% up from the prior year.
  • Equity Income hit -$3508.0 in Q2 2023 for Silo Pharma, up from -$74821.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$3508.0 in Q2 2023 to a low of -$74821.0 in Q4 2022.